Drugs / Investigational live attenuated varicella vaccine
Investigational live attenuated varicella vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02965404 | Apr → May 2016 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05839301 | Apr → Jul 2023 | chickenpox | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05150392 | Jul → Aug 2018 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational live attenuated varicella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02965404 ↗ |
| Modality | Vaccine | “investigational live attenuated varicella vaccine” NCT02965404 ↗ |
| Route | Intramuscular | “Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0” NCT02965404 ↗ |